Latest Breaking News On - Roberta hauser - Page 1 : comparemela.com

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

TOXINS 2021: New analyses of pivotal Phase III trial data highlight long duration of response for Dysport® (abobotulinumtoxinA) in five therapeutic indications -Today at 12:08 pm

Analyses of pivotal study data of Dysport® reveal a large proportion of study patients did not require retreatment for at least 12 weeks This new analysis.

JAMA Neurology Publishes Phase 3 Study Results Comparing IPX203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

- IPX203 demonstrated statistically significant improvement in daily “Good On” time compared to optimized IR CD/LD, with fewer daily doses .

IPX203 provides more relief in fewer daily doses for Parkinson's with motor fluctuations

Robert A. Hauser, MD, MBA, of the Parkinson's Disease and Movement Disorders Center, University of South Florida, joins Vial's Neurology CRO Scientific Advisory Board

/PRNewswire/ Vial welcomes Robert A. Hauser, MD, MBA, as a new Central Nervous System (CNS) advisory board member to their Neurology CRO. Dr. Hauser is the.